Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
12.98 NOK | +0.62% | +0.15% | -39.35% |
Sales 2024 * | 157M 14.24M 19.3M | Sales 2025 * | 190M 17.22M 23.34M | Capitalization | 4.24B 384M 521M |
---|---|---|---|---|---|
Net income 2024 * | -613M -55.6M -75.34M | Net income 2025 * | -735M -66.67M -90.33M | EV / Sales 2024 * | 19 x |
Net cash position 2024 * | 1.25B 114M 154M | Net cash position 2025 * | 1.01B 91.53M 124M | EV / Sales 2025 * | 17 x |
P/E ratio 2024 * |
-6.97
x | P/E ratio 2025 * |
-6.25
x | Employees | 172 |
Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 55% |
Latest transcript on Nykode Therapeutics
1 day | +0.62% | ||
1 week | +0.15% | ||
Current month | -13.41% | ||
1 month | -14.83% | ||
3 months | -31.76% | ||
6 months | -22.92% | ||
Current year | -39.35% |
Managers | Title | Age | Since |
---|---|---|---|
Founder | 47 | 06-12-31 | |
Michael Engsig
CEO | Chief Executive Officer | - | 07-02-28 |
Harald Gurvin
DFI | Director of Finance/CFO | 49 | 21-05-02 |
Members of the board | Title | Age | Since |
---|---|---|---|
Bernd Seizinger
BRD | Director/Board Member | 67 | - |
Director/Board Member | 64 | - | |
Director/Board Member | - | - |
Name | Weight | AuM | 1st Jan change | Investor Rating |
---|---|---|---|---|
0.01% | 773 M€ | -.--% | - | |
0.00% | 10 M€ | -3.35% | - | |
0.00% | 152 M€ | -3.56% | - | |
0.00% | 26 M€ | -4.26% | - |
Date | Price | Change | Volume |
---|---|---|---|
24-04-26 | 12.98 | +0.62% | 639,229 |
24-04-25 | 12.9 | -3.01% | 600,010 |
24-04-24 | 13.3 | -0.82% | 507,883 |
24-04-23 | 13.41 | +1.90% | 425,178 |
24-04-22 | 13.16 | +1.54% | 538,941 |
Real-time Oslo Bors, April 26, 2024 at 10:45 am
More quotesEPS Revisions
1st Jan change | Capi. | |
---|---|---|
-39.35% | 384M | |
-2.31% | 103B | |
+0.56% | 95.28B | |
+1.69% | 22.15B | |
-17.37% | 21.02B | |
-9.30% | 18.15B | |
-41.01% | 16.74B | |
-14.85% | 16.05B | |
+3.21% | 13.68B | |
+33.54% | 12.17B |
- Stock Market
- Equities
- VACC Stock